Overview

Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to study the evaluation of efficacy and safety of GreenGene (Recombinant Factor VIII).
Phase:
Phase 3
Details
Lead Sponsor:
Green Cross Corporation
Treatments:
Factor VIII